Nano-Polymer Stents May Reach U.S. Market By 2007 At Half The Cost Of DES
This article was originally published in The Gray Sheet
Executive Summary
Polyphosphaze non-carbon-based nano-polymers potentially will offer the same anti-restenosis benefits as drug-eluting stents, but cost only slightly more than bare-metal versions, according to Götz Richter, MD/PhD, University of Heidelberg, Germany
You may also be interested in...
Can Better Polymers Challenge DES? Cost Barriers Spur German Alternative
Coronary stents coated with non-carbon-based polymers may prevent restenosis without bearing drugs, Götz Richter, MD/PhD, University of Heidelberg, Germany, asserted Nov. 18
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.